• Board approved audited FY26 results with 36.7% revenue growth to ₹206.38 crore and net profit of ₹31.15 crore.
• Statutory auditors issued unmodified opinion on standalone financial statements for year ended March 31, 2026.
• Company operates as single pharmaceutical segment with 95% of revenue from export sales outside India.
• Board meeting held on May 21, 2026 from 5:00 PM to 5:25 PM to review financial results and reports.